Journal
FUTURE MEDICINAL CHEMISTRY
Volume 8, Issue 12, Pages 1485-1501Publisher
Newlands Press Ltd
DOI: 10.4155/fmc-2016-0050
Keywords
ABC and MFS transporters; antifungal drug resistance; azole; chemosensitzation; heterologous expression; high-throughput screen
Categories
Funding
- NIH [R01-DE016855-01, R03-MH087406-1A1, U54 MH074425/MH086490]
- Royal Society of New Zealand Marsden Fund [UOO1305]
- Health Research Council of New Zealand's International Investment Opportunities Fund [IIOF 09_04]
- Health Research Council of New Zealand
- University of Otago
Ask authors/readers for more resources
Resistance to antifungal drugs is an increasingly significant clinical problem. The most common antifungal resistance encountered is efflux pump-mediated resistance of Candida species to azole drugs. One approach to overcome this resistance is to inhibit the pumps and chemosensitize resistant strains to azole drugs. Drug discovery targeting fungal efflux pumps could thus result in the development of azole-enhancing combination therapy. Heterologous expression of fungal efflux pumps in Saccharomyces cerevisiae provides a versatile system for screening for pump inhibitors. Fungal efflux pumps transport a range of xenobiotics including fluorescent compounds. This enables the use of fluorescence-based detection, as well as growth inhibition assays, in screens to discover compounds targeting efflux-mediated antifungal drug resistance. A variety of medium-and high-throughput screens have been used to identify a number of chemical entities that inhibit fungal efflux pumps.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available